Targeting histone deacetylases in testicular germ cell tumours: an encouraging treatment approach for the future

J Pathol. 2023 Feb;259(2):115-118. doi: 10.1002/path.6037. Epub 2022 Dec 20.

Abstract

Epidrugs, specifically histone deacetylase inhibitors (HDACi), have been increasingly used in preclinical studies for the treatment of testicular germ cell tumours (TGCTs). SINHCAF was recently described as a potential oncogene in TGCTs located on chromosome 12p, the hallmark of type II (malignant) TGCTs. The findings contribute to the field by further supporting the efficacy of HDACi in the treatment of TGCTs, promoting the design of more preclinical studies and providing the motivation for future implementation of clinical studies with these compounds. © 2022 The Pathological Society of Great Britain and Ireland.

Keywords: cisplatin; epidrugs; epigenetics; histone deacetylase inhibitors; testicular germ cell tumours.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Male
  • Neoplasms, Germ Cell and Embryonal* / drug therapy
  • Neoplasms, Germ Cell and Embryonal* / genetics
  • Testicular Neoplasms* / drug therapy
  • Testicular Neoplasms* / genetics
  • Testicular Neoplasms* / pathology
  • United Kingdom

Supplementary concepts

  • Testicular Germ Cell Tumor